Every year, over 1,800 women in Ghana lose their lives to cervical cancer—a staggering number that demands our urgent attention. But here’s where it gets even more alarming: many of these deaths could be prevented with a simple yet powerful tool—the Human Papilloma Virus (HPV) vaccine. Dr. Ali Samba, President of the Society of Obstetricians and Gynaecologists of Ghana (SOGOG), has passionately emphasized that this vaccine can slash the risk of cervical cancer by up to 90% when administered before exposure. Speaking at SOGOG’s Annual General and Scientific Meeting (AGSM) in Koforidua, he highlighted the vaccine’s potential to save lives, but also pointed out the hurdles that stand in the way.
The three-day AGSM gathered obstetricians, gynaecologists, health professionals, and development partners to tackle one of Ghana’s most pressing health challenges. Cervical cancer remains the second most common cancer among women in the country, and despite advancements in screening and treatment, many women still arrive at health facilities with advanced stages of the disease, where treatment options are limited. The World Health Organization (WHO) reports that Ghana sees approximately 3,000 new cases and over 1,800 deaths annually—a grim reminder of the work that lies ahead.
And this is the part most people miss: Dr. Samba identified several barriers to the effective rollout of the HPV vaccine, including coverage gaps, public misconceptions, logistical challenges, and broader health system limitations. He urged clinicians, researchers, and health advocates to combat misinformation with clarity, empathy, and scientific accuracy. “We must use our platforms to build trust in this life-saving vaccine,” he stated, calling for a future where no woman in Ghana dies from cervical cancer.
The WHO’s country representative to Ghana, Dr. Fiona Braka, praised Ghana’s first nationwide HPV vaccination campaign, which successfully vaccinated approximately 84% of the targeted 2.2 million girls. She noted that the absence of serious side effects during the campaign underscores the vaccine’s safety. “Following this success, the HPV vaccine is now part of Ghana’s routine immunization schedule,” she added.
However, here’s where it gets controversial: while the campaign’s success is undeniable, questions remain about how to sustain momentum and address lingering public skepticism. Dr. Kennedy Brightson, Director of the Family Health Division of the Ghana Health Service (GHS), called for renewed commitment and innovative strategies to overcome these challenges. He reaffirmed the GHS’s dedication to expanding HPV screening and vaccination nationwide, emphasizing efforts to strengthen screening, expand treatment services, improve early diagnosis, and support research in women’s health.
The event also marked the launch of Ghana’s Cervical Cancer Prevention and Treatment Guidelines, an evidence-based framework designed to reduce cervical cancer incidence, morbidity, and mortality while promoting health equity and universal health coverage. These guidelines are a significant step forward, but their success will depend on effective implementation and community engagement.
Now, here’s a thought-provoking question for you: With the HPV vaccine proven safe and effective, why do misconceptions and logistical challenges still hinder its widespread adoption? Is it a matter of education, infrastructure, or something deeper? Share your thoughts in the comments—let’s spark a conversation that could save lives.
